Stock Yards Bank & Trust Co. Has $17.15 Million Stock Holdings in Johnson & Johnson $JNJ

Stock Yards Bank & Trust Co. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 8.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 112,266 shares of the company’s stock after selling 10,729 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Johnson & Johnson were worth $17,149,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Apexium Financial LP grew its stake in shares of Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after acquiring an additional 2,310 shares in the last quarter. Avanza Fonder AB boosted its holdings in Johnson & Johnson by 2.9% in the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after purchasing an additional 6,566 shares during the period. Joel Isaacson & Co. LLC increased its holdings in shares of Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after purchasing an additional 2,526 shares during the period. Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Johnson & Johnson by 7.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock valued at $12,164,000 after buying an additional 4,816 shares during the period. Finally, Range Financial Group LLC grew its position in Johnson & Johnson by 18.9% during the first quarter. Range Financial Group LLC now owns 15,886 shares of the company’s stock worth $2,635,000 after buying an additional 2,529 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on JNJ. Barclays lifted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Citigroup increased their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, August 21st. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday. Finally, Royal Bank Of Canada upped their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $188.88.

Johnson & Johnson Trading Up 1.4%

Shares of NYSE JNJ opened at $188.51 on Monday. The firm has a 50 day moving average price of $176.18 and a two-hundred day moving average price of $162.83. The stock has a market cap of $453.98 billion, a P/E ratio of 20.16, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $189.78. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.